안구건조증 치료 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 약제별, 제품별, 제형별, 판매채널별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type, By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,876,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,368,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,351,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

안구건조증 치료 시장 성장과 동향

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 안구건조증 치료 시장 규모는 2025-2030년에 CAGR 6.5%로 확대하며, 2030년에는 92억 달러에 달할 것으로 추정되고 있습니다.

시장의 성장은 스크린 사용 증가, 노인 인구 증가, 안과 질환 유병률 증가 등의 요인에 기인합니다.

스크린 기기 사용 증가, 컴퓨터 사용 급증, 눈 깜빡임 횟수 감소 등으로 인해 전 세계에서 증발성 안구건조증 증후군이 증가하고 있습니다. 예를 들어 2021년 Frontiers Journal에 따르면 COVID-19 팬데믹 기간 중 성인의 스크린 사용은 팬데믹 이전과 비교했을 때 60-80% 증가했다고 합니다. 스크린에 노출되면 눈 깜빡임 횟수가 66% 감소하여 눈물의 증발을 촉진하여 안구건조증을 유발할 수 있습니다.

처방약의 수용률이 매우 낮기 때문에 일반의약품(OTC)이 시장의 주류로 자리 잡고 있습니다. 예를 들어 안구건조증 진단을 받은 환자 중 10%만이 처방전 없이 안약을 사용하고 있으며, 75%는 처방전 없이 안약을 사용해 본 적이 없는 것으로 나타났습니다. 하지만 안구건조증 진단을 받은 환자 수는 전체 안과 진료의 5-35%를 차지합니다.

또한 자이드라나 레스타시스와 같은 기존 제품들은 효과가 나타나기까지 몇 달에서 몇 주가 걸립니다. 또한 안과 의사들에 따르면 이들 제품은 내약성 문제가 있으며, 실패율이 50%에 달할 전망입니다. 따라서 시장에는 미충족 수요가 존재하며, 향후 수년간 출시될 파이프라인 제품에 유리한 기회가 생길 것으로 예상됩니다. 또한 의약품 관련 규제가 전체 시장의 성장을 저해하는 요인으로 작용하고 있습니다. 예를 들어 2020년 노바티스는 규제 당국이 크시드라의 사용에 대해 큰 이의를 제기함에 따라 유럽에서 크시드라의 사용을 자발적으로 철회해야만 했습니다.

주요 기업의 혁신과 전략적 노력이 시장을 주도하고 있습니다. 신제품 출시는 각 회사가 채택하고 있는 것반적인 전략입니다. 예를 들어 2021년 10월 오이스터 포인트 파마(Oyster Point Pharma)의 타이르바야(Tyrvaya) 비강 스프레이(바레니클린 용액)가 대체 치료법으로 FDA의 승인을 받았습니다.

안구건조증 치료제 시장 보고서 하이라이트

• 유형별로는 증발성 안구건조증이 2024년 가장 큰 시장 점유율을 차지하고 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 제형별로는 점안제/액체가 2024년 64.68%로 가장 큰 점유율을 차지하며 시장을 장악했습니다.
• 약제별로는 2024년 Xiidra 부문이 8.52%의 매출 점유율로 전체 시장을 장악했습니다.
• 유통 채널별로는 편의성 때문에 온라인 약국에 대한 소비자 선호도가 높아지면서 온라인 약국이 예측 기간 중 가장 빠른 속도로 성장할 것으로 예상됩니다.
• 북미는 높은 질병 유병률, 인지도의 급상승, 치료율 향상으로 2023년 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 안구건조증 치료 시장 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 안구건조증 치료 시장 분석 툴
  • 산업 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 안구건조증 치료 시장 : 유형별, 추정·동향 분석

• 부문 대시보드
• 안구건조증 치료 시장 : 유형 변동 분석
• 안구건조증 치료 시장 : 유형별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 증발성 안구건조증
• 눈물결핍성 안구건조증

제5장 안구건조증 치료 시장 : 약제별, 추정·동향 분석

• 부문 대시보드
• 안구건조증 치료 시장 : 약제 변동 분석
• 안구건조증 치료 시장 : 약제별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• Xiidra
• Restasis
• Cequa
• Tyrvaya
• Eysuvis
• 기타

제6장 안구건조증 치료 시장 : 제품별, 추정·동향 분석

• 부문 대시보드
• 안구건조증 치료 시장 : 제품 변동 분석
• 안구건조증 치료 시장 : 제품별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 인공눈물
• 시클로스포린
• 국소 코르티코스테로이드
• 누점 플러그
• 경구 오메가 보충제
• 기타

제7장 안구건조증 치료 시장 : 제형별, 추정·동향 분석

• 부문 대시보드
• 안구건조증 치료 시장 : 제형 변동 분석
• 안구건조증 치료 시장 : 제형별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 점안약/용액
• 연고와 젤
• 캡슐·태블릿(보충제용)
• 기타

제8장 안구건조증 치료 시장 : 판매채널별, 추정·동향 분석

• 부문 대시보드
• 안구건조증 치료 시장 : 판매채널 변동 분석
• 안구건조증 치료 시장 : 판매채널별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 처방
• OTC
• 기타

제9장 안구건조증 치료 시장 : 유통 채널별, 추정·동향 분석

• 부문 대시보드
• 안구건조증 치료 시장 : 유통 채널 변동 분석
• 안구건조증 치료 시장 : 유통 채널별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 소매 약국
• 병원 약국
• 온라인 약국

제10장 안구건조증 치료 시장 : 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제11장 경쟁 구도

• 기업 분류
• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업 시장 점유율 분석, 2024년
• 기업 개요
  • Novartis AG
  • AbbVie, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Santen Pharmaceutical Co Ltd.
  • AFT Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.(Otsuka Holdings Co., Ltd.의 자회사)
  • OASIS Medical
  • Oyster Point Pharma, Inc.(2023년 1월에 Viatris Inc.에 인수)
  • Bausch Health Companies, Inc.

KSA

영문 목차

영문목차

Dry Eye Syndrome Treatment Market Growth & Trends:

The global dry eye syndrome treatment market size is estimated to reach USD 9.20 billion by 2030, expanding at a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.

The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60-80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.

Over-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.

Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.

Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.

Dry Eye Syndrome Treatment Market Report Highlights:

• By type, Evaporative dry eye syndrome segment dominated the market with the largest market share in 2024 and is also anticipated to grow with the fastest CAGR during the forecast period
• Based on dosage form, The eye drops/ solutions segment dominated the market with the largest share of 64.68% in 2024
• By drug, The Xiidra segment dominated the overall market in 2024, with a revenue share of 8.52%.
• Based on distribution channel, online pharmacies are expected to grow at the fastest rate over the forecast period due to the increased consumer preference for online pharmacies owing to the convenience
• North America dominated the market in 2023 due to the high prevalence of the disease, surging awareness, and enhanced treatment rate

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drugs
  • 1.2.3. Product
  • 1.2.4. Dosage Form
  • 1.2.5. Sales Channel
  • 1.2.6. Distribution Channel
  • 1.2.7. Regional Scope
  • 1.2.8. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Drugs outlook
  • 2.2.3. Product outlook
  • 2.2.4. Dosage form outlook
  • 2.2.5. Sales channel outlook
  • 2.2.6. Distribution channel outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Dry Eye Syndrome Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing geriatric population
    • 3.2.1.2. Increasing prevalence of dry eye syndrome
    • 3.2.1.3. Robust product pipeline
    • 3.2.1.4. Growing disease awareness and increasing use of contact lenses
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Competition from generic products
    • 3.2.2.2. High cost of treatments and lack of awareness among the general population in low- and middle-income countries
• 3.3. Dry Eye Syndrome Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Dry Eye Syndrome Treatment Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Dry Eye Syndrome Treatment Market: Type Movement Analysis
• 4.3. Dry Eye Syndrome Treatment Market by Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Evaporative Dry Eye Syndrome
  • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.6. Aqueous Deficient Dry Eye Syndrome
  • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Dry Eye Syndrome Treatment Market: Drugs Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Dry Eye Syndrome Treatment Market: Drugs Movement Analysis
• 5.3. Dry Eye Syndrome Treatment Market by Drugs Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Xiidra
  • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6. Restasis
  • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.7. Cequa
  • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.8. Tyrvaya
  • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.9. Eysuvis
  • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Dry Eye Syndrome Treatment Market: Product Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Dry Eye Syndrome Treatment Market: Product Movement Analysis
• 6.3. Dry Eye Syndrome Treatment Market by Product Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Artificial Tears
  • 6.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6. Cyclosporine
  • 6.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.7. Topical Corticosteroids
  • 6.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.8. Punctal Plugs
  • 6.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.9. Oral Omega Supplements
  • 6.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7. Dry Eye Syndrome Treatment Market: Dosage Form Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Dry Eye Syndrome Treatment Market: Dosage Form Movement Analysis
• 7.3. Dry Eye Syndrome Treatment Market by Dosage Form Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Eye Drops/ Solutions
  • 7.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6. Ointments and Gels
  • 7.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7. Capsules & Tablets (For Supplements)
  • 7.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.8. Other Dosage Forms
  • 7.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8. Dry Eye Syndrome Treatment Market: Sales Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Dry Eye Syndrome Treatment Market: Sales Channel Movement Analysis
• 8.3. Dry Eye Syndrome Treatment Market by Sales Channel Outlook (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Prescription
  • 8.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6. OTC
  • 8.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Dry Eye Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Dry Eye Syndrome Treatment Market: Distribution Channel Movement Analysis
• 9.3. Dry Eye Syndrome Treatment Market by Distribution Channel Outlook (USD Million)
• 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 9.5. Retail Pharmacies
  • 9.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.6. Hospital Pharmacies
  • 9.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.7. Online Pharmacies
  • 9.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 10. Dry Eye Syndrome Treatment Market: Regional Estimates & Trend Analysis

• 10.1. Regional Dashboard
• 10.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 10.3. North America
  • 10.3.1. U.S.
    • 10.3.1.1. Key country dynamics
    • 10.3.1.2. Regulatory framework/ reimbursement structure
    • 10.3.1.3. Competitive scenario
    • 10.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.2. Canada
    • 10.3.2.1. Key country dynamics
    • 10.3.2.2. Regulatory framework/ reimbursement structure
    • 10.3.2.3. Competitive scenario
    • 10.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.3. Mexico
    • 10.3.3.1. Key country dynamics
    • 10.3.3.2. Regulatory framework/ reimbursement structure
    • 10.3.3.3. Competitive scenario
    • 10.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 10.4. Europe
  • 10.4.1. UK
    • 10.4.1.1. Key country dynamics
    • 10.4.1.2. Regulatory framework/ reimbursement structure
    • 10.4.1.3. Competitive scenario
    • 10.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.2. Germany
    • 10.4.2.1. Key country dynamics
    • 10.4.2.2. Regulatory framework/ reimbursement structure
    • 10.4.2.3. Competitive scenario
    • 10.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.3. France
    • 10.4.3.1. Key country dynamics
    • 10.4.3.2. Regulatory framework/ reimbursement structure
    • 10.4.3.3. Competitive scenario
    • 10.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.4. Italy
    • 10.4.4.1. Key country dynamics
    • 10.4.4.2. Regulatory framework/ reimbursement structure
    • 10.4.4.3. Competitive scenario
    • 10.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.5. Spain
    • 10.4.5.1. Key country dynamics
    • 10.4.5.2. Regulatory framework/ reimbursement structure
    • 10.4.5.3. Competitive scenario
    • 10.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.6. Norway
    • 10.4.6.1. Key country dynamics
    • 10.4.6.2. Regulatory framework/ reimbursement structure
    • 10.4.6.3. Competitive scenario
    • 10.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.7. Sweden
    • 10.4.7.1. Key country dynamics
    • 10.4.7.2. Regulatory framework/ reimbursement structure
    • 10.4.7.3. Competitive scenario
    • 10.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.8. Denmark
    • 10.4.8.1. Key country dynamics
    • 10.4.8.2. Regulatory framework/ reimbursement structure
    • 10.4.8.3. Competitive scenario
    • 10.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Japan
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework/ reimbursement structure
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.2. China
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework/ reimbursement structure
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.3. India
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework/ reimbursement structure
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.4. Australia
    • 10.5.4.1. Key country dynamics
    • 10.5.4.2. Regulatory framework/ reimbursement structure
    • 10.5.4.3. Competitive scenario
    • 10.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.5. South Korea
    • 10.5.5.1. Key country dynamics
    • 10.5.5.2. Regulatory framework/ reimbursement structure
    • 10.5.5.3. Competitive scenario
    • 10.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.6. Thailand
    • 10.5.6.1. Key country dynamics
    • 10.5.6.2. Regulatory framework/ reimbursement structure
    • 10.5.6.3. Competitive scenario
    • 10.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 10.6. Latin America
  • 10.6.1. Brazil
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework/ reimbursement structure
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.2. Argentina
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework/ reimbursement structure
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 10.7. MEA
  • 10.7.1. South Africa
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework/ reimbursement structure
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.2. Saudi Arabia
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework/ reimbursement structure
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.3. UAE
    • 10.7.3.1. Key country dynamics
    • 10.7.3.2. Regulatory framework/ reimbursement structure
    • 10.7.3.3. Competitive scenario
    • 10.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.4. Kuwait
    • 10.7.4.1. Key country dynamics
    • 10.7.4.2. Regulatory framework/ reimbursement structure
    • 10.7.4.3. Competitive scenario
    • 10.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
• 11.2. Recent Developments & Impact Analysis by Key Market Participants
• 11.3. Company Market Share Analysis, 2024
• 11.4. Company overview
  • 11.4.1. Novartis AG
    • 11.4.1.1. Company Overview
    • 11.4.1.2. Financial performance
    • 11.4.1.3. Product benchmarking
    • 11.4.1.4. Strategic initiatives
  • 11.4.2. AbbVie, Inc.
    • 11.4.2.1. Company Overview
    • 11.4.2.2. Financial performance
    • 11.4.2.3. Product benchmarking
    • 11.4.2.4. Strategic initiatives
  • 11.4.3. Sun Pharmaceutical Industries Ltd.
    • 11.4.3.1. Company Overview
    • 11.4.3.2. Financial performance
    • 11.4.3.3. Product benchmarking
    • 11.4.3.4. Strategic initiatives
  • 11.4.4. Santen Pharmaceutical Co Ltd.
    • 11.4.4.1. Company Overview
    • 11.4.4.2. Financial performance
    • 11.4.4.3. Product benchmarking
    • 11.4.4.4. Strategic initiatives
  • 11.4.5. AFT Pharmaceuticals
    • 11.4.5.1. Company Overview
    • 11.4.5.2. Financial performance
    • 11.4.5.3. Product benchmarking
    • 11.4.5.4. Strategic initiatives
  • 11.4.6. Johnson & Johnson Services, Inc.
    • 11.4.6.1. Company Overview
    • 11.4.6.2. Financial performance
    • 11.4.6.3. Product benchmarking
    • 11.4.6.4. Strategic initiatives
  • 11.4.7. Otsuka Pharmaceutical Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd.)
    • 11.4.7.1. Company Overview
    • 11.4.7.2. Financial performance
    • 11.4.7.3. Product benchmarking
    • 11.4.7.4. Strategic initiatives
  • 11.4.8. OASIS Medical
    • 11.4.8.1. Company Overview
    • 11.4.8.2. Financial performance
    • 11.4.8.3. Product benchmarking
    • 11.4.8.4. Strategic initiatives
  • 11.4.9. Oyster Point Pharma, Inc. (acquired by Viatris Inc. in January 2023)
    • 11.4.9.1. Company Overview
    • 11.4.9.2. Financial performance
    • 11.4.9.3. Product benchmarking
    • 11.4.9.4. Strategic initiatives
  • 11.4.10. Bausch Health Companies, Inc.
    • 11.4.10.1. Company Overview
    • 11.4.10.2. Financial performance
    • 11.4.10.3. Product benchmarking
    • 11.4.10.4. Strategic initiatives

관련자료